Alligator Bioscience AB Interim Report January-September 2017

Significant events, July-September

• Aptevo Therapeutics and Alligator Bioscience signed a co-development agreement on the bispecific antibody ALG.APV-527. Preclinical development and initial production activities for clinical trial materials for ALG.APV-527 commenced.

• The immuno-oncology collaboration with Stanford University was expanded. The aim is to predict the clinical efficacy of Alligator’s pipeline candidates using biomarkers.

• A research contract was signed with Professor Ignacio Melero, MD, PhD, from the University of Navarra in Spain, for 4-1BB as a target molecule in immunotherapy and cancer therapy.

• The results of the Alligator-led Phase I clinical trial for ADC-1013/JNJ-64457107 will be presented at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November.

• Janssen’s Phase I clinical trial for ADC-1013/JNJ-64457107 is ongoing with approximately 50 patients recruited to date.

Events after the end of the period

Alligator and collaboration partner Aptevo Therapeutics announced on 24 October that the tumor antigen 5T4, associated with many forms of solid tumors, is the second target for ALG.APV-527.

Financial summary

July-September

• Net sales, SEK 1.8 million (4.7).
• Operating loss, SEK 24.5 million (loss: 9.1).
• Loss for the period, SEK 25.8 million (loss: 7.5).
• Loss per share, SEK 0.36 (loss: 0.13).
• Cash and cash equivalents incl. bonds, SEK 588 million (659).

January-September

• Net sales, SEK 5.6 million (51.8).
• Operating loss, SEK 73.0 million (loss: 34.0)
• Loss for the period, SEK 76.3 million (loss: 29.0)
• Loss per share, SEK 1.07 (loss: 0.49)
• Cash flow for the period was a negative SEK 141.5 million (neg: 23.8), of which SEK 74.5 million was invested in corporate bonds.
• During the period, 1,275,000 warrants (230,000) were exercised for an equivalent number of shares.

Financial summary (Group)

2017

2016

2017

2016

2016

 

Jul-Sep

 

Jul-Sep

 

Jan-Sep

 

Jan-Sep

Jan-Dec

 

Net sales, TSEK

 

1,770

 

4,661

 

5,576

 

51,808

 

58,240

 

Operating profit/loss, TSEK

 

-24,459

 

-9,133

 

-73,032

 

-33,952

 

-56,082

 

Profit/loss for the period, TSEK 

 

-25,772

 

-7,545

 

-76,274

 

-29,008

 

-48,356

 

Cash flow for the period, TSEK

 

-25,409

 

-17,780

 

-141,479

 

-23,759

 

287,135

 

Cash and cash equivalents including bonds, TSEK

 

587,578

 

346,457

 

513,220

 

346,457

 

659,136

 

Equity ratio, %

 

97%

 

97%

 

97%

 

97%

 

96%

 

R&D costs as % of operating costs excluding impairments

 

69.3%

 

58.3%

 

69.5%

 

62.2%

 

64.3%

 

Earnings per share before dilution, SEK

 

-0.36

 

-0.13

 

-1.07

 

-0.49

 

-0.80

 

Earnings per share after dilution, SEK

 

-0.36

 

-0.13

 

-1.07

 

-0.49

 

-0.80

 

Average number of employees

 

43

 

33

 

40

 

31

31

The complete report is attached in the link below.

For further information, please contact:

Per Norlén
CEO
[email protected]
+46-46-286-42-80

Per-Olof Schrewelius
CFO
[email protected]
+46-46-286-42-85

Rein Piir
VP IR
[email protected],
+46-46-286-42-80

Alligator Bioscience AB (publ) 556597-8201
Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden.
Phone +46-46-286-42-80
www.alligatorbioscience.com

Alligator Bioscience AB (publ) is obligated to make public the information contained in this report pursuant to the EU Market Abuse Regulation and the Securities Markets Act. This information was provided to the media, through the agency of the contact persons set out above, for publication on October 25, 2017 at 08.00 a.m. CEST.

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/alligator-bioscience/r/alligator-bioscience-ab-interim-report-january-september-2017,c2374749

The following files are available for download:

SOURCE Alligator Bioscience

Powered by WPeMatico

You might like

About the Author: Carrie Brunner

Carrie Brunner grew up in a small town in northern New Brunswick. She studied chemistry in college, graduated, and married her husband one month later. They were then blessed with two baby boys within the first four years of marriage. Having babies gave their family a desire to return to the old paths – to nourish their family with traditional, homegrown foods; rid their home of toxic chemicals and petroleum products; and give their boys a chance to know a simple, sustainable way of life. They are currently building a homestead from scratch on two little acres in central Texas. There’s a lot to be done to become somewhat self-sufficient, but they are debt-free and get to spend their days living this simple, good life together with their five young children. Carrie writes mostly on provincial stories.
%d bloggers like this: